Nebivolol Aurovitas (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractile force, which lowers cardiac output and blood pressure. It also enhances nitric‑oxide release from the endothelium, causing vasodilation that further contributes to its antihypertensive effect.

The exact dose of Nebivolol Aurovitas is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other medications. Physicians typically start with a low dose and may adjust it to achieve optimal blood pressure or heart‑failure control.

Safety data for Nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Nebivolol Aurovitas product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nebivolol is a highly selective β1‑blocker that also promotes nitric‑oxide‑mediated vasodilation, offering a favorable side‑effect profile compared with non‑selective beta blockers. It tends to cause less bronchoconstriction and may have a lower incidence of metabolic disturbances, making it a preferred option for patients with concomitant respiratory or metabolic concerns.

Nebivolol Aurovitas should be stored at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Nebivolol Aurovitas is taken orally, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent blood levels.

The most serious adverse events to monitor include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with asthma or COPD, and rare cases of acute heart‑failure decompensation. Prompt medical attention is required if any of these symptoms develop.

Nebivolol is contraindicated in patients with severe bradycardia (heart rate <50 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, decompensated heart failure, or known hypersensitivity to the drug. Caution is also advised for individuals with significant liver disease or uncontrolled asthma.